Israel requires updated labelling for topiramate and fluoroquinolones due to safety concerns
This article was originally published in SRA
Executive Summary
The Pharmaceutical Administration of the Israeli Ministry of Health has issued a circular requiring an immediate update of the labelling of topiramate tablets, namely, the physician prescribing information and the patient information leaflet, approved for marketing in Israel. It has also issued a separate circular requiring local manufacturers and importers of medicinal products to update immediately the labelling of all fluoroquinolone products. Both circulars were issued on 13 March.